期刊文献+

破骨细胞相关因子在骨再建过程中表达的定量分析 被引量:4

Quantitative Study of Osteoclastic Related Factors in the Process of Bone Reconstruction
下载PDF
导出
摘要 目的研究肿瘤坏死因子-α(TNF-α)、核因子-κB受体激动剂(RANKL)、抗酒石酸酸性磷酸酶(TRAP)在骨再建过程中的表达。方法用8周龄雄性C57BL/6J小鼠建立骨折模型,用RT-PCR法对骨形成过程中TNF-α、 RANKL和TRAP的表达进行时程分析。结果骨折后TNF-α、RANKL、TRAP的表达均上调,但峰值在不同的时间点出现。TNF-α在骨折后2 d达峰值,BANKL的峰值出现在骨折5 d后,而TRAP的表达在骨折后10 d达到峰值。结论骨的再建也有破骨细胞相关因子的参与,它有赖于成骨和破骨的精确平衡。 Objective To detect the expression of osteoclast related factors, tumor necrosis factor-α (TNF-α), receptor activator of NF-kB ligand (RANKL) and tartrate-resistant acid phosphatase (TRAP), in the process of bone remodeling. Methods 8-week-old male C57BL/6J mice were employed in this study to detect the expression of osteoclast related factors by real time PCR. Results TNF-α, RANKL and TRAP were up regulated in the process of bone remodeling, they reached the peak on day 2, 5 and 10 individually after injury. Conclusion Osteoclast related factors also participate in bone remodeling, which depends on the delicate balance between bone formation and bone resorption.
出处 《华西口腔医学杂志》 CAS CSCD 北大核心 2006年第2期164-165,169,共3页 West China Journal of Stomatology
基金 辽宁省自然科学基金资助项目(619022) 辽宁省博士启动基金资助项目(2001102069) 日本文部科学省博士后基金资助项目(02262)
关键词 肿瘤坏死因子 核因子-kB受体激动剂 抗酒石酸酸性磷酸酶 实时定量聚合酶链反应 骨再建 tumor necrosis factor, receptor activator of NF-kB ligand tartrate-resistant acid phosphatase real time polymerase chain reaction bone remodeling
  • 相关文献

参考文献9

  • 1Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor β superfamily during murine fracture healing[J].J Bone Miner Res,2002,17(3):513-520.
  • 2Canalis E, Eonomides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton[J]. Endocr Rev,24(2) :218-235.
  • 3Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β[J]. Nature, 2002, 416(6882):744-749.
  • 4Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisma and implications for the pathogenesis and treatment of osteoporosis[J]. Endocr Rev, 2000, 21 (2): 115-137.
  • 5Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL[J]. Proc Natl Acad Sci U S A, 1998, 95 (7):3597-3602.
  • 6Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families[J]. Endocr Rev, 1999,20 (3) : 345-357.
  • 7Gerstenfeld LC, Cho TJ, Kon T, et al. Impaired fracture healing in the absence of TNF-alpha signaling: The role of TNF-alpha in endochondral cartilage resorption[J]. J Bone Miner Res, 2003,18(9) : 1584-1592.
  • 8Roggia C, Gao Y, Cenci S, et al. Up-regualtion of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo[J]. Proc Natl Acad Sci U S A,2001, 98(24): 13960-13965.
  • 9Abu-Amer Y, Ross FP, Edwards J, et al. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor[J]. J Clin Invest, 1997, 100(6):1557-1565.

同被引文献76

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部